Journal of Thoracic Disease 2022 August [Link] Olivia Lauk, Thomas Neuer, Bianca Battilana, Ilhan Inci, Katarzyna Furrer, Walter Weder, Masaki Hashimoto, Isabelle Opitz Abstract Background: Malignant pleural mesothelioma (MPM) is associated with high rates of local recurrence (LR) up to 75%. Second line treatment should be applied tailored to relapse pattern. We aimed to establish…

Read More

Journal of Thoracic Oncology 2022 September 5 [Link] Michael Offin, Dilanka De Silva, Jennifer L Sauter, Jacklynn V Egger, Ellen Yorke, Prasad S Adusumilli, Andreas Rimner, Valerie W Rusch, Marjorie G Zauderer Abstract Background: Primary pericardial mesothelioma (PPM) has no accepted standard of care treatment options with management and outcomes often extrapolated from diffuse pleural…

Read More

Thoracic Cancer 2022 September 2 [Link] Francesco Falanga, Pietro Rinaldi, Cristiano Primiceri, Chandra Bortolotto, Olga Oneta, Francesco Agustoni, Patrizia Morbini, Laura Saracino, Dimitrios Eleftheriou, Federico Sottotetti, Giulia Maria Stella Abstract Surgery is part of a multimodal therapeutic approach to malignant pleural mesothelioma (MPM) although its real beneficial effect is still controversial. The optimal precise sequence…

Read More

Cancer Medicine 2022 August 28 [Link] Yue Jiang, Chengda Zhang, Yang Chen, Shiyu Zhao, Yipeng He, Jun He Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and highly malignant thoracic tumor. Although alternative splicing (AS) is associated with tumor prognosis, the prognostic significance of AS in MPM is unknown. Methods: Transcriptomic data, clinical information,…

Read More

Experimental Oncology 2022 August [Link] D Endoh, K Ishii, K Kohno, N Virgona, Y Miyakoshi, T Yano, T Ishida Abstract Background: Hypoxia has been noted as a key factor for induction and maintenance of cancer stemness thereby leading to therapy resistance. Three-dimensional (3D) spheroid models demonstrate a heterogeneity of hypoxic regions replicating the in vivo…

Read More

Journal of Clinical Medicine 2022 August 3 [Link] Giuseppe Mangiameli, Edoardo Bottoni, Umberto Cariboni, Giorgio Maria Ferraroli, Emanuela Morenghi, Veronica Maria Giudici, Emanuele Voulaz, Marco Alloisio, Alberto Testori Abstract Objectives: We examined a series of malignant pleural mesothelioma (MPM) patients who consecutively underwent surgery in our institution during the last 20 years. Across this period,…

Read More

Frontiers in Public Health 2022 July 22 [Link] Zhuo-Miao Ye, Zi-Qing Tang, Zhe Xu, Qin Zhou, Huan Li Abstract Background: The treatment paradigm of unresectable malignant pleural mesothelioma (MPM) has changed in recent years. Checkmate 743 demonstrate that nivolumab plus ipilimumab showed good clinical benefits compared with chemotherapy in the treatment of MPM. The study…

Read More

BioMed Research International 2022 July 27 [Link] M Shobana, V R Balasraswathi, R Radhika, Ahmed Kareem Oleiwi, Sushovan Chaudhury, Ajay S Ladkat, Mohd Naved, Abdul Wahab Rahmani Abstract Cancer of the mesothelium, sometimes referred to as malignant mesothelioma (MM), is an extremely uncommon form of the illness that almost always results in death. Chemotherapy, surgery,…

Read More

Targeted Oncology 2022 July [Link] Fatéméh Dubois, Céline Bazille, Jérôme Levallet, Elodie Maille, Solenn Brosseau, Jeannick Madelaine, Emmanuel Bergot, Gérard Zalcman, Guénaëlle Levallet Abstract Malignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos in…

Read More

Oncology Letters 2022 June 28 [Link] Francesco Di Meo, Roberta Esposito, Rossana Cuciniello, Gregorio Favale, Mario Arenga, Nadia Ruocco, Genoveffa Nuzzo, Angelo Fontana, Stefania Filosa, Stefania Crispi, Maria Costantini Abstract The serious side effects caused by chemotherapeutics and the development of cancer chemoresistance represent the most significant limitations in the treatment of cancer. Some alternative…

Read More